REG - C4X Discovery - Board Change

C4X Discovery HoldingsAnnouncement

19/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211119:nRSS8990Sa&default-theme=true

RNS Number : 8990S  C4X Discovery Holdings PLC  19 November 2021

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Board Change

 

 

19 November 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces that Craig Fox, Chief Scientific Officer
("CSO"), has informed the Company of his intention to step down from his role
and the Board, after six years of service, to pursue a new opportunity. Craig
is expected to leave the Company by 31 March 2022 and a search for a new CSO
has commenced. A further announcement will be made in due course.

 

Clive Dix, Chief Executive Officer of C4X Discovery, commented: "Craig has
been an important part of the C4XD team and his scientific know-how and
expertise has contributed to a plethora of exciting scientific discoveries
that have led to the signing of major outlicensing agreements. On behalf of
the Board, I would like to express my sincere gratitude to Craig for his
dedication and valuable contribution to the Company during his six years of
service. We wish Craig continued success in all his future endeavours."

 

Craig Fox commented: "I have thoroughly enjoyed my time at C4XD, and it has
been a privilege to work with its fantastic people and to see the Company
transform through its AIM-listing and subsequent multiple partnering deals. I
believe the team's world-class scientific expertise, tenacity, and dedication,
combined with proprietary cutting-edge technologies provide a truly
ground-breaking capability that can efficiently deliver world-leading
medicines that can meaningfully impact the lives of patients. I wish the team
well as I move on to my next role and look forward to hearing about their next
achievements."

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early stage novel target
opportunities to late stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFVLLFFFLXFBV